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EDITORIAL REVIEW
The clinical significance of inhibition of renal prostaglandin
synthesis
Clinical interest in renal prostaglandins has been stimulated
by the repeated observation that nonsteroidal anti-inflammatory
drugs (NSAD) can decrease renal function [1—4]. The purpose
of this editorial review is to analyze the physiologic significance
of renal prostaglandin synthesis and the pathophysiologic con-
sequences of inhibition of prostaglandin production through the
use of NSAD. In order to adequately develop this theme, it is
necessary to review some biochemical principles of eicosanoid
synthesis.
Eicosanoid is the generic term which refers to lipoxygenase
and cyclooxygenase products of arachidonic acid metabolism.
Figure 1 outlines some of these pathways. Prostaglandins and
the other eicosanoids are autacoids which do not have a
circulating, endocrine function but rather act in a paracrine or
autocrine manner affecting cells close to or at the site of
prostaglandin synthesis [5]. NSAD inhibit either irreversibly
(aspirin) or reversibly the cyclooxygenase enzymes which
convert arachidonic acid to the prostaglandin endoperoxides
[61. Presently, no similar inhibitory agents are clinically avail-
able which inhibit the lipoxygenase enzymes converting arachi-
donic acid to leukotrienes and monohydroxy fatty acids. Al-
though glucocorticoids can limit substrate availability through
the induction of a recently characterized phospholipase A2-
inhibitory protein named lipocortin [7], their in vivo effects on
endogenous prostaglandin production are rather inconsistent [8,
9]. Recent in vitro studies support the concept that corticoster-
oids inhibit mitogen—induced T-cell proliferation by suppressing
endogenous LTB4 production [10].
Localization of renal prostaglandin synthesis
Eicosanoid synthesis in the kidney is localized to specific
sites and is not uniformly present throughout the nephron [5].
Since the initial discovery of prostaglandin synthesis in the
renal medulla, it has been recognized that medullary tissue
synthesizes greater amounts of prostaglandins than the cortex
[11]. It is generally accepted that the regional heterogeneity of
arachidonate metabolism, as well as the lack of vascular com-
munications between the medulla and cortex, dictate that
prostaglandins synthesized in the cortex (glomeruli and vascu-
lature) regulate cortical function and prostaglandins synthe-
sized in the medulla (collecting tubule and medullary interstitial
cells) regulate medullary function [5]. Table I summarizes the
principal sites of prostaglandin synthesis in the kidney, the
major prostaglandins produced at each site, and their principal
actions. Assessment of prostaglandin synthesis by different
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components of the nephron is based on immunofluorescent
microscopy [12—14], separation of glomeruli and nephron seg-
ments with measurement of prostaglandin synthesis [15—17] or
by cell cultures of specific components of the nephron with
measurement of eicosanoid turnover [18—22]. Some species
variation exists and the majority of data are based on studies of
rat, rabbit, and human kidney. In the cortex, the major sites of
prostaglandin synthesis include arteries, arterioles and the
glomerulus. The proximal tubule and the loop of Henle show
little cyclooxygenase activity, but may convert arachidonate to
several epoxygenase derivatives [reviewed in 23]. The large
amounts of PGE2 produced by the renal medulla primarily
derive from the substantial biosynthetic activity of collecting
tubule and interstitial cells. Eicosanoids synthesized within the
kidney are either degraded in the kidney, by enzymes acting on
the M3,14 double bond and on the hydroxyl group at C-iS, or
are removed from the kidney in the lymphatic and venous
drainage or by excretion into the urine [5]. As discussed below,
measurement of urinary unmetabolized prostaglandins or their
stable hydrolysis products provides the best clinical assessment
of the state of renal prostaglandin production.
Does urinary prostaglandin excretion reflect intrarenal
prostaglandin synthesis?
In vivo studies of renal prostaglandin synthesis, based on the
assessment of renal secretory and/or excretory rates of PGE2
and PGF2a, have been reported in several species including the
rat, rabbit, dog and humans [reviewed in 24]. Renal venous
prostaglandins are presumably derived from direct venous
drainage of cellular sites of synthesis and also from venous
removal of reabsorbed prostaglandins. Measurement of unme-
tabolized prostaglandins in renal venous plasma, however,
suffers from major limitations, that is, very low levels, platelet
synthesis during and after sampling (only partially prevented by
cyclooxygenase inhibitors), and invasive procedure. As a con-
sequence, measurement of unmetabolized prostaglandins in
urine has gained general acceptance following the original
report by Frolich et al [25] suggesting their renal origin in
healthy women. Besides having a two orders of magnitude
higher prostaglandin concentration, urine has the additional
advantage over renal venous plasma of being free of platelet
eicosanoids and of providing a noninvasive, continuous rather
than episodic measure of renal prostaglandin synthesis. A
number of methodologic as well as biologic variables can,
however, affect urinary prostaglandin measurements in human
studies. These include storage conditions (due to chemical
instability of some eicosanoids), purification and assay methods
(due to the presence in urine of a large array of structurally
related eicosanoids), and possible contribution from extrarenal
sources [26]. Thus, trace amounts of seminal fluid, having l0 to
Fig. 1. Summary of prostaglandin and
thromboxane formation from arachidonic
acid. The site of action of nonsteroidal
antiinflammatory drugs is indicated on the
cyclooxygenase enzyme which converts
arachidonic acid to PG endoperoxides.
Site Eicosanoid Action
Vasculature PGI. Vasodilation
Glomerulus PGI2, PGE
TxA2
Maintain GFR
Reduce GFR°
Collecting tubule PGE2, PGF2,. Enhance excretion of NaCl
and water
Medullary interstitial PGE2 Vasodilation and natriure-
cells sis—diuresis
106 higher PGE2 concentration than urine, can contribute a
highly variable though substantial fraction of the measured
urinary PGE2 in man, making the overall interpretation of such
measurements highly questionable [27]. In addition to the
"classical" primary prostaglandins, that is, PGE2 and PGF2a,
human urine contains measurable amounts of 6-keto-PGF1a [28]
and TXB2 [29], chemically stable hydration products of PGI2
and TXA2, respectively. Drugs that selectively spare renal
cyclooxygenase activity, such as sulindac or low—dose aspirin
[30], do not reduce the urinary excretion of 6-keto-PGF1a and
TXB2 in health [31—33] and disease [31, 34]. Human diseases
have been characterized in which markedly—elevated urinary
excretion of 6-keto-PGF1a (Bartter's syndrome) or TXB2 (sys-
temic lupus erythematosus) were proven to reflect enhanced
intrarenal production of PG!2 [35] or TXA2 [36], respectively,
on the basis of unchanged excretion of the major urinary
metabolites reflecting an extra—renal origin [371, that is, 2,3-
dinor-6-keto-PGFia and 2,3-dinor-TXB2.
Radioimmunoassay (RIA) as well as gas chromatography—
mass spectrometry have been employed to quantitate urinary
prostaglandin and thromboxane excretion [25, 26, 38, 39].
While the latter can provide definitive identification of a given
eicosanoid, with adequate sensitivity particularly in the nega-
tive ion, chemical ionization mode [39], the former represents a
highly sophisticated form of bioassay substituting the classical
smooth—muscle strip with a soluble antibody as the biological
reactant. Consequently, the biological read—out, that is variably
reduced binding of the labeled eicosanoid to a presumably
"specific" anti-eicosanoid serum as a function of increasing
concentrations of the unlabeled homologous ligand, is liable to
all forms of artifacts possibly affecting bioassay. In particular,
the presence in urine of a large number of potentially cross—
reacting enzymatic derivatives of prostaglandins and thrombox-
ane B2 excreted in a 10- to 100-fold excess vis-a-vis unmetab-
olized eicosanoids represents a serious potential limitation to
the specificity of such measurements. Unfortunately, immuno-
logic characterization of anti-eicosanoid sera is often limited to
primary prostaglandins and TXB2 with limited information, if
any, on the cross—reactivity of major urinary metabolites such
as the 2,3-dinor—derivatives of PGI2 and TXB2. Moreover,
reduction of the measured urinary prostaglandin—like immuno-
reactivity by cyclooxygenase inhibitors is often presented as
evidence of the "specificity" of such measurements - This may
be misleading, inasmuch as the renal and extra—renal synthesis
of all eicosanoids will be suppressed by non-selective cyclooxy-
genase inhibitors (such as indomethacin) thereby causing a
simultaneous reduction in the urinary excretion of both primary
unmetabolized prostaglandins (presumably reflecting a renal
origin) and potentially cross—reacting systemic metabolites. On
the other hand, such methodologic problems will confound the
effects of selective cyclooxygenase inhibitors on the kidney
(such as sulindac, low—dose aspirin, sulfinpyrazone) by virtue
of the reduced excretion of cross—reacting systemic metabolites
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Table 1. Principal renal sites of prostaglandin synthesis and major
actions
a TxA2 reduces GFR in pathophysiologic situations such as glomeru-
lonephritis, transplant rejection, and ureteral obstruction.
Adapted from [5].
Inhibition of renal prostaglandin synthesis 3
masking the continued synthesis and excretion of renal prosta-
glandins.
Reliable etiteria allowing the assessment of the specificity of
urinary PG measurements by RIA include: a) characterization
of the thin—layer or high—pressure liquid chromatographic pat-
tern of distribution of the extracted prostaglandin—like immuno-
reactivity; b) use of multiple antisera; and c) comparison with
mass spectrometric determinations [28, 36]. Such an integrated
approach can provide meaningful information on renal prosta-
glandin and thromboxane synthesis in health and disease.
Finally, it should be pointed out that urinary prostaglandins
only represent a fraction of total renal synthesis, with substan-
tial amounts of prostaglandins degraded by or secreted into the
renal venous blood. Furthermore, renal venous blood as well as
urinary unmetabolized prostaglandins probably manifest an
heterogeneous origin within the kidney, since no data are
available to indicate a preferential secretion or excretion of
prostaglandins by any particular component of the nephron.
Purely on the basis of differential eicosanoid production in
isolated human glomeruli and papillae [40] it could be specu-
lated that urinary 6-keto-PGF1a and TXB2 primarily reflect the
glomerular synthesis of PG!2 and TXA2, respectively. How-
ever, human medullary synthesis of PGI2 has been shown in
vitro [411. Urinary PGE2 may be largely a result of medullary
PGE2 production. The medullary origin of urinary PGE2 is
supported by experiments showing 75% reductions of urine
PGE2 after chemical inedullectomy induced by bromethylamine
[42].
Renal prostaglandin—synthesis inhibition by NSAD in man
Drug induced inhibition of renal prostaglandin synthesis is
thought to be reflected by a variably reduced excretion of
primary unmetabolized prostaglandins [24—26]. The specific
detection of such pharmacologic changes is severely hampered
by a) the virtually ubiquitous distribution of the enzyme cyclo-
oxygenase and b) the ratio of urinary eicosanoid metabolites to
primary prostaglandins being 10—100 to 1. Particularly, in the
case of a selective sparing of renal cyclooxygenase activity [30],
the continued excretion of renal prostaglandins can be largely
or totally obscured in the face of a concomitant reduction in the
elimination of extrarenal eicosanoid metabolites. Inasmuch as
biochemical measurements, putatively related to renal cyclo-
oxygenase activity, are used to interpret drug—induced changes
in renal function and to project clinical implications, it is of
utmost importance to establish some criteria for the validity of
such measurements. Short of providing definitive proof of
identification by obtaining a full mass—spectrum of the urinary
eicosanoid of interest [25], validation criteria of radioim-
munologic measurements should include the following:
1) a prerequisite is that such studies be conducted in female
subjects inasmuch as primary prostaglandins may largely
derive from extra—renal (seminal) sources in male urine
[27];
2) evidence that urinary prostaglandin—like immunoreactiv-
ity is reduced by >50% following the acute and/or chronic
administration of a nonselective cyclooxygenase inhibitor
(such as indomethacin) at antiinflammatory dosage;
3) evidence that extra-renal eicosanoid metabolites (such as,
PGE-M, PGF-M, 2,3-dinor-6-keto-PGF1a, 2,3-dinor-
TXB2) do not contribute to the apparent prostaglandin—
like immunoreactivity, through cross—reactivity studies
and/or comparison with an independent method of analy-
sis [28, 36];
4) under appropriate pathophysiologic conditions, evidence
for a functional correlate (that is, changes in renal blood
flow, glomerular filtration rate, renin secretion and/or
sodium chloride excretion) of reduced renal prostaglan-
din—synthesis.
Most, if not all, widely used NSAD have been tested for their
acute and/or chronic effects on urinary prostaglandin excretion.
These include indomethacin [43—46], ibuprofen [34, 43, 44, 47,
48], naproxen [47—50], aspirin [33, 51], fenoprofen [47],
diclofenac [49, 52], sulindac [32, 34, 45, 46, 48, 49, 50, 52—63],
piroxicam [49], and flurbiprofen [52]. Their effects have been
characterized in healthy subjects [32, 33, 45, 46, 48, 53, 63] as
well as in patients with renal [34, 43, 47, 51, 52, 55, 58], hepatic
[44, 56, 57, 61, 62], rheumatic [49, 50] and cardiovascular [50,
54, 59, 60] disease. Some generalizations can be drawn from the
results of such studies: a) with the possible exception of
sulindac (see below), all of these NSAD have been shown to
reduce urinary prostaglandin excretion by at least 50% when
used at full antiinflammatory dosage; a maximal reduction in the
range of 60 to 80% has been described with the vast majority of
these agents, although no detailed dose—response studies have
been carried out to allow a quantitative assessment of relative
potencies; b) such a maximal suppression of renal prostaglandin
synthesis can be shown to occur within 24 to 48 hours of
treatment, and is fully reversible within 48 to 72 hours after drug
withdrawal, depending upon the pharmacokinetics of the indi-
vidual agent; c) the apparent reduction in urinary prostaglandin
excretion following a given cyclooxygenase inhibitor is not
substantially modified by disease processes affecting renal or
hepatic function, although the latter can obviously alter the
pharmacokinetics of some NSAD; d) despite early reports of
partial attenuation of NSAD-induced biochemical and func-
tional changes during continued drug administration [47], such
a phenomenon has not been confirmed in controlled studies
[34].
In 1980, Ciabattoni et al [32] reported that renal prostaglandin
excretion in healthy women and patients with Bartter's syn-
drome was not decreased by sulindac, possibly because of its
redox pro-drug nature confining formation and/or access of its
active sulfide metabolite to extra—renal sites of cyclooxygenase
activity [65]. These preliminary observations were later ex-
tended and confirmed by ourselves [34, 45, 49, 63] as well as by
other investigators [46, 52, 54, 58—62]. However, several studies
in health [48, 53] as well as in disease [50, 55—57] have reported
conflicting evidence regarding the biochemical selectivity of
sulindac.
As clarification of this issue is relevant to the interpretation of
changes in renal function and cardiovascular homeostasis asso-
ciated with NSAD administration, we shall attempt to briefly
outline the different views and factors possibly responsible for
the conflicting findings. In doing so, we shall review separately
those studies that have measured urinary eicosanoid excretion
in the basal state from those studies that have quantitated the
effect of sulindac during i.v. furosemide—enhanced diuresis. An
overview of 18 studies (123 patients) falling in the former
category, is presented in Table 2. Obviously, two different
views have been expressed by the investigators involved in
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Table 2. Overview of published studies assessing the effects of sulindac (400 mg/day) treatment (ito 28 days) on urinary eicosanoid excretion
in health and disease
Authors (ref.)
No. of
subjects
.Clinical
condition
Treatment
days
Validation criteria
PGE2 PGF2. 6-Keto-PGF1, TXB21 2 3 4
Berg & Talseth (55) 8 RD 2 — + — — ND ND ND
Brater et al (48) 11 N I — — — — No A ND No A ND
Ciabattoni et al (34) 10 RD 7 + + + + No A ND No A ND
Ciabattoni et al (49) 5 RA 7 + + + No A No A No A No A
Ciabattoni et al (63) 7 N 7 ND ND No A ND
Guarner et al (62) 5 LD I ? — + — ND ND No A No A
Laffi et a! (56) 10 LD 5 — + — — ND No A
Laffi et a! (61) 4 LD 6 — + — No A ND No A No A
Mistry et al (58) 5 RD 9 + — — + No A ND No A ND
Nadler et al (46) 7 N 3 ND ND No A ND
Puddey et a! (59) 9 EH 28 — + No A ND No A ND
Quintero et al (57) 5 LD 3 ? — — + I ND I ND
Roberts et al (53) 5 N 5 + + + — I ND ND ND
Salvetti et a! (54) 9 EH 7 — + ND ND No A ND
Salvetti et al (60) 5 EH 7 — + — -I- ND ND No A ND
Sedor et a! (45) 5 N 4 + + — + No A No A No A ND
Svendsen et al (50) 10 CD 14 — — ND ND
Vriesendorp et al (52) 3 RD 7—10 — + — + No A ND ND ND
Validation criteria 1—4 are those described in the text for the assessment of radioimmunologic measurements of urinary eicosanoids in man.
Abbreviations are: Criteria met, +; not met, equivocal, No A, not significantly different from control or placebo; I , significantly lower than
control or placebo; ND, not determined; N, normal; RD. renal disease; LD, liver disease; CD, cardiac disease; EH, essential hypertension; RA,
rheumatoid arthritis.
such studies. One view maintains that sulindac is qualitatively
different from other NSAD in selectively sparing renal cyclo-
oxygenase activity. The best evidence supporting this view
comes from studies comparing sulindac to another NSAD in the
same clinical situation [34, 45, 46, 49, 52, 54, 59, 60] using RIA
methods that have been validated by GC/MS [34, 46, 49], and
including a functional correlate (that is, measurement of renal
function and/or blood pressure) of reduced versus unchanged
urinary prostaglandin—excretion [34, 45, 46, 52, 54, 58—60].
Possible flaws in these studies could be related to: a) failure to
detect a reduction of urinary prostaglandin excretion because
sulindac administration might be associated with the urinary
excretion of a metabolite cross—reacting with anti-prostaglandin
serum and simulating higher prostaglandin concentrations in
urine of treated subjects; or b) failure to detect a small reduction
(that is, 30 to 40%) in renal prostaglandin synthesis as statisti-
cally significant because of inadequate sample size. The other
view held by different investigators implies that sulindac is only
quantitatively different from other NSAD in being a weaker
cyclooxygenase inhibitor on all tissues, including the kidney
[53, 56]. Five studies (evaluating a total of 38 patients) have
found a statistically significant reduction in urinary PGE2 ex-
cretion by 47 to 85% [50, 53, 55—57]. Potential flaws in these
studies are related to the validation criteria of radioimmuno-
logic measurements discussed above and detailed in Table 2. In
contrast, only one study [57] has demonstrated a significant
reduction in urinary 6-keto-PGF1a, a major cyclooxygenase
product of human glomeruli [40]. Interestingly, this occurred in
five patients with cirrhosis and ascites having circulating plasma
concentrations of the active sulfide metabolite which were
fourfold higher than drug levels measured in healthy controls.
This study was also the only report of a clear—cut functional
correlate of reduced prostaglandin excretion by sulindac, that
is, a reduction in glomerular filtration rate. In contrast, no
statistically—significant functional changes were measured by
Berg and Talseth [55] or Laffi et al [56] despite 47 and 65%
reductions in urinary PGE2 excretion, respectively, in patients
with PG-dependent renal function (see below). Three studies
have evaluated the effects of sulindac on in vivo indices of
extra—renal cyclooxygenase activity [53, 62, 63]. Roberts et al
[53] measured the urinary excretion of the tetranor metabolite
of PGF2,, and found it to be significantly reduced by both
indomethacin (by 43%) and sulindac (by 35%). By intergroup
comparison, the two drugs did not differ from each other.
Ciabattoni et al [63] measured the excretion of 2,3-dinor 6-keto-
PGF1, the major urinary metabolite of systemic PG!2 produc-
tion [37], and found the prostacyclin metabolite excretion to be
reduced dose—dependently by sulindac in the range of 200 ing to
800 mg per day (each dose given for 7 days in successive
weeks), with 56% reduction at 400 mg/day. Guarner et al [62]
measured the same metabolite in five cirrhotic patients with
ascites and described an 85% suppression of its urinary excre-
tion, despite unchanged excretory rates of 6-keto-PGF1,,. and
TXB2. These results should be taken into proper consideration
in future studies of sulindac employing RIA techniques for the
measurement of urinary prostaglandins and TXB2, inasmuch as
cross—reactivity of 2,3-dinor-6-keto PGF1a and 2,-3-dinor TXB2
with antisera directed against 6-keto PGF1,. and TXB2 can be as
great as 20 to 50% [28, 36].
Three independent studies [48, 53, 66] have reviewed the
effects of sulindac on PGE2 excretion in response to a bolus
injection of furosemide, a drug known to cause an acute
stimulation of renal eicosanoid excretion [291. The studies of
Brater et al [48] and Roberts et a! [53] in healthy subjects as well
as the study of Daskalopoulos et al [66] in patients with
cirrhosis and ascites consistently showed a blunting of furose-
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mide—enhanced POE2 excretion after sulindac. Although
merely a theoretical speculation, the above findings could be
consistent with a differential oxidation of the sulfide metabolite
of sulindac in the medulla as compared to the cortex, thereby
exposing medullary sites (primarily synthesizing PGE2) but not
cortical sites (primarily synthesizing PGI2) of cyclooxygenase
activity to effective concentrations of the biologically active
form of the drug. The mechanism(s) responsible for the alleged
biochemical selectivity of sulindac is still poorly understood. It
is not related to a differential sensitivity of the renal cyclooxy-
genase to the drug, since in vitro comparison of sulindac sulfide
and indomethacin using renal medullary interstitial cells and
papillary collecting tubule cells in culture showed sulindac
sulfide to be equipotent to indomethacin as an inhibitor of POE2
synthesis [64]. Differential inhibition of renal and extra—renal
prostaglandin synthesis might be related to the redox pro-drug
nature of sulindac [65], as suggested by similar observations
made with sulfinpyrazone [67]. Animal studies [68—73] have
yielded similarly conflicting results, depending upon the animal
species, experimental design, dosage and route of administra-
tion of sulindac. The study by Miller, Bednar and McGiff [74] in
the isolated perfused kidney of the rabbit and rat has estab-
lished that: a) the kidney possesses the metabolic pathways for
the interconversion of sulindac sulfoxide and sulfide as well as
sulfone formation; b) whereas all three forms exist in renal
tissue, the sulfide is inactivated before its release into venous or
urinary effluents; c) administration of either sulindac sulfide or
sulfoxide can result in effective cyclooxygenase inhibition.
Thus, to summarize our own experience and personal reading
of the current literature on this rather controversial issue: 1)
when given to human subjects at the recommended therapeutic
dose of 400 mg/day, sulindac does not appear to influence
cortical sites of renal cyclooxygenase activity, as reflected by
urinary 6-keto-PGF,a, with the possible exception of patients
with cirrhosis and ascites; 2) under the same circumstances, the
drug may affect medullary sites of cyclooxygenase activity, as
reflected by urinary POE2, in approximately one third of the
cases thus far evaluated; 3) the drug does appear to blunt i.v.
furosemide—induced PGE2 release; 4) the mechanism(s) under-
lying these peculiar features of sulindac is largely unknown,
although likely related to its redox pro-drug nature.
A different mechanism is responsible for the selective sparing
of renal cyclooxygenase activity by low—dose aspirin [33]. The
mechanism underlying this selectivity is probably related to a
different rate of recovery of cyclooxygenase activity in glomer-
uli versus platelets, following irreversible acetylation of the
enzyme, and possibly to a different aspirin "sensitivity" of
glomerular cyclooxygenase. The finding of a normal pattern of
furosemide—induced renin release and urinary 6-keto-PGF1,
excretion after three to four weeks of low—dose (0.45 mg/kg/
day) aspirin treatment in healthy subjects [33] indicates that
renal PGI2-producing cells are readily activatable at a time of
virtually complete suppression of platelet cyclooxygenase ac-
tivity. Thus, low-dose aspirin represents an ideal pharmacolog-
ic tool to investigate the role of intraglomerular platelet activa-
tion in the progression of chronic glomerular disease [75]
without the risk inherent to higher conventional dosage which
might compromise prostaglandin—dependent renal function.
The effects of prostaglandins and nonsteroidal antiinflammatory
drugs on renal cortical and medullary functions
Renal function is not dependent upon the integrity of
prostaglandin synthesis, at least under ordinary circumstances.
Inhibition of prostaglandin synthesis in normal animals and
humans does not induce a significant decline of renal function
[1]. It is probable that basal, endogenous prostaglandin synthe-
sis does contribute to control of renal vascular resistance,
glomerular filtration and salt excretion in healthy subjects, but
administration of NSAD does not alter renal function since
other regulatory mechanisms (adrenergic tone, renin secretion,
dopamine, adenosine) are unstressed and can compensate for
the inhibition of prostaglandins [5]. In animals under anesthe-
sia, especially after laparotomy, acute inhibition of prostaglan-
din synthesis reduces renal blood flow substantially, although
glomerular filtration rate is largely unaffected [76]. Different
responses of anesthetized surgically—stressed dogs and con-
scious animals to the acute inhibition of prostaglandin synthesis
are partially attributable to the effects of anesthesia and surgery
on major vasoconstrictor hormones, especially angiotensin II,
vasopressin, and catecholamines. In experimental and clinical
circumstances, in which these vasoconstrictor hormones are
increased, renal prostaglandin synthesis is augmented and renal
function becomes "prostaglandin dependent" [5]. Infusion of
angiotensin II, vasopressin, or norepinephrine into the renal
artery stimulates renal prostaglandin synthesis measured either
as secretion into renal venous blood or excretion into the urine
[77—81]. In vitro studies have confirmed that angiotensin and
vasopressin stimulate vasodilatory prostaglandin release in
glomerular mesangial and epithelial cells, and renal medullary
interstitial cells [19—21, 82, 83]. Pretreatment with nonsteroidal
antiinflammatory agents potentiated the renal vasoconstriction
induced by angiotensin II, alpha-adrenergic nerve stimulation,
and norepinephrine or alpha adrenergic drugs [S4—89]. These
experiments reinforce the belief that the vasoconstrictor sub-
stances stimulated renal cortical and medullary POE2 and P012
which modulated the constrictor action of the angiotensin or
norepinephrine. The major clinical circumstances in which
vasoconstrictor hormones increase to maintain cardiovascular
homeostasis include extracellular volume depletion, congestive
heart failure, nephrotic syndrome and hepatic disease.
Diseases such as arteriosclerotic cardiovascular disease and
chronic glomerular disease (including lupus nephritis) may
reduce renal POE2 or P012 [34, 36] and thereby enhance the
susceptibility to NSAD despite normal levels of constrictor
hormones. Figure 2 summarizes our hypothesis about the
modulating effect of renal POE2 and P012 on the intrarenal
constrictor action of angiotensin II, vasopressin, and norepi-
nephrine. According to this hypothesis, drug— and/or disease—
induced suppression of cortical prostaglandin synthesis is asso-
ciated with a lower threshold for the contractile response of the
glomerular mesangium and arterioles to a variety of agonists.
This simplified scheme does not include the important possibil-
ity that glomerular and vascular PGE2 and P012 may antagonize
the renal effects of diverse contractile compounds, such as
platelet activating factor, thromboxane A2, leukotriene C4-D4,
and other vasoconstrictor agents. Perhaps more prevalent than
the acute changes in glomerular filtration rate and renal blood
flow observed above is NSAD-induced sodium retention.
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Constrictor hormone
Fig. 2. Scheme depicting the balance between vasoconstriction and
vasodilatation existing in the pre- and post-glomerular circulation, and
the glonierular Inesangium. Abbreviations include: arteriosclerotic
cardiovascular disease (ASCVD); chronic glomerulonephritis (CGN);
systemic lupus erythematosus (SLE); congestive heart failure (CHF);
angiotensin II (ANG LI); nonsteroidal antiinflammatory drugs (NSAD).
The graph schematically depicts the enhanced arteriolar and mesangial
contraction to constrictor hormones after inhibition of prostaglandin
synthesis.
Edema has been reported to occur in approximately 25% of
patients with arthritis who were receiving either aspirin or
fenoprofen and in about 10% of patients who were given
ibuprofen [2]. The mechanisms underlying the retention of
sodium associated with NSAD administration are probably
multifactorial and have been discussed previously [1—5]. Water
retention that is disproportionate to sodium retention may lead
to the development of hyponatremia in some patients, particu-
larly as a result of the combined use of NSAD and thiazides
causing an additive effect on free—water excretion, as empha-
sized by Clive and Stoff [2]. In addition, NSAD may produce
hyperkalemia by inducing hyporeninemic hypoaldosteronism as
first shown by Tan et a! [90]. In a prospective study of 50
patients requiring indomethacin treatment for various medical
reasons, 13 patients developed an increase in serum potassium
concentration equal to or greater than 1.0 mM/liter within three
to seven days of treatment [91]. These patients were character-
ized as being elderly (68 12 yrs) and with a relatively high
(6 1%) prevalence of pre-existing mild to moderate azotemia.
The vast majority of clinical studies published prior to 1985
have been discussed extensively in previous reviews of the
subject [1—4]. It is important to realize that NSAD-induced
changes in cortical and/or medullary functions have been doc-
umented in short—term studies, that is, one day to four weeks of
treatment (5 to 7 days in most studies). The long—term conse-
quences of chronic administration of renal prostaglandin syn-
thesis inhibitors are largely unknown. In the next section, we
will review clinical and experimental studies published during
the last two years, which have primarily focused on the
comparative evaluation of sulindac versus other NSAD in
health and disease.
The effects of sulindac on renal function: Experimental and
clinical studies
Interest in a possible renal—sparing effect of sulindac can be
attributed to the clinical prevalence of acute renal failure as a
complication of nonsteroidal antiinflammatory drug therapy. A
majority of studies, summarized below, show negligible deteri-
oration of renal function when sulindac is administered orally in
conventional doses. In normal volunteers, glomerular filtration
rate, measured as either creatinine clearance or inulin clear-
ance, was unaffected by sulindac [32, 45, 53, 92]. These results
in normal volunteers are not surprising as other nonsteroidal
antiinflammatory drugs, such as indomethacin and ibuprofen,
also have no effect on GFR in normal volunteers, despite
substantial inhibition of renal prostaglandin synthesis [1]. Sedor
et al also did not observe any reductions of urine Na or Cl after
sulindac administration, whereas indomethacin substantially
reduced salt excretion in normal volunteers [45].
A possible renal—sparing action of sulindac has been best
demonstrated in patients with liver disease or chronic renal
failure. Patients with alcoholic cirrhosis and ascites treated with
either indomethacin or sulindac have very different renal func-
tional responses to these NSAD. Daskalopoulous et al [66]
administered indomethacin, 50 mg two hours and eight hours
prior to study and found reduced glomerular filtration rate by
approximately 50% accompanied by substantial decrements of
urinary PGE2. In similar cirrhotic patients, sulindac, 150 mg
two and eight hours prior to evaluation, reduced glomerular
filtration rate insignificantly (15%) with no changes in urinary
prostaglandin excretion. Despite the absence of any sulin-
dac—induced decrement of renal function in these experiments,
sulindac as well as indomethacin antagonized furosemide—
stimulated prostaglandin excretion and furosemide—induced
natriuresis and diuresis [66]. Laffi and coworkers studied ten
patients with alcoholic cirrhosis and ascites in a comparison of
sulindac 200 mg twice daily for five days, followed by ibuprofen
400 mg every eight hours for one day [56]. Sulindac did not
reduce glomerular filtration rate or renal plasma flow whereas
ibuprofen induced substantial decrements of these renal hemo-
dynamic parameters in five of the ten cases. Quintero et al [57]
have obtained contrasting results as they observed reductions
of glomerular filtration rate and prostaglandin excretion of 39%
and 78% in five patients with cirrhosis and ascites who received
sulindac 400 mg a day for three days. These workers noted, as
did Laffi et al, that patients with liver disease have significantly
increased plasma levels of the active component of sulindac,
sulindac sulfide. These observations of 2.5 [56] to fourfold [57]
increases in plasma sulindac sulfide levels, after conventional
oral doses to cirrhotic patients, confirm the earlier work of Juhl
et al [93] who found that the area under the curve for plasma
sulindac sulfide increased fourfold in patients with poor hepatic
function. These results raise a note of caution about the
administration of sulindac, particularly in conventional doses,
to patients with severe hepatic dysfunction. Zambraski and
coworkers, studying dogs with biliary cirrhosis and portal
hypertension, also documented high plasma sulindac sulfide
levels for prolonged periods of time after intravenous adminis-
tration of sulindac [68]. In these animals, who had chronic bile
duct ligation, sulindac or sulindac sulfide acutely decreased
GFR and RPF.
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Patients with mild to moderate chronic renal failure (GFR of
90 21 mI/mm) have been compared for their responses to
NSAD by Ciabattoni and coworkers [34]. Twenty women with
chronic glomerular disease were treated with either ibuprofen
or sulindac for seven days. Whereas ibuprofen reduced glomer-
ular filtration rate and renal plasma flow by 35%, sulindac had
no significant effect on renal function or prostaglandin excretion
[34]. These results have been confirmed by others. In patients
with greater reductions of GFR (37 to 41 ml/min) indomethacin
but not sulindac reduced filtration 25% and decreased PGE2
excretion to a greater extent [55]. Swainson and Grifliths
evaluated six patients with chronic renal disease and basal
glomerular filtration rates of 18 to 48 ml/min [92]. Twenty—eight
days of treatment with sulindac, 600 mg per day, induced
negligible (12%) or no changes in renal plasma flow and glomer-
ular filtration rate, respectively. As one patient did have greater
decrements of renal plasma flow and glomerular filtration rate,
the authors conclude that although sulindac is relatively safe, an
occasional patient may develop acute renal failure [92]. Acute
reversible decline of renal function, attributable to sulindac, has
been reported in only two other cases. Blackshear et al [3, 94]
described an 81 year—old woman with hypertension and atrial
fibrillation, receiving diuretic therapy, who was treated with
sulindac 800 mg over 24 hours. She suffered reversible in-
creases in blood urea nitrogen and serum creatinine. Corwin
and Bonventre reported the case of a 79 year—old woman,
treated with sulindac 150 mg twice daily, with concomitant
problems of congestive heart failure, hypertension and
adult—onset diabetes mellitus [95]. Renal function declined
substantially and, with cessation of sulindac therapy, the pa-
tient recovered over 10 days. These cases highlight the possi-
bility that elderly patients with cardiovascular and renal disease
may develop acute renal failure despite any relative, renal—spar-
ing effect of sulindac. Despite pretreatment GFR of 37 mllmin,
nine patients with chronic renal failure studied by Mistry et al
[58] had only 10% decrements of GFR and no changes of RPF
after nine days therapy with sulindac. Consistent with human
studies, the administration of sulindac (30 mg/kg over 48 hours)
to 5/6 nephrectomized rats had no effect on renal function,
electrolyte excretion or renal PGE2 production [691. In con-
trast, indomethacin dramatically reduced the urinary excretion
of Na and the fractional excretion of Na in these animals,
concomitantly with a marked suppression of renal PGE2 pro-
duction [69]. Other reports do not confirm that sulindac has no
effects on renal prostaglandin synthesis or GFR in experimental
animals. Sulindac, compared to indomethacin and naproxen,
reduced urine PGE2, free water clearance, and GFR to a similar
extent in sodium—depleted rats [71]. Measurements of renal
venous 6-keto-PGF1 in rats after endotoxin [70] or dogs after
hemorrhagic hypotension [72] also demonstrated inhibition of
PG!2 synthesis after parenteral administration of sulindac.
Henrich, Brater and Campbell, using the model of hemorrhagic
hypotension in the dog, measured comparable reductions of
GFR, RBF and renal venous 6-keto-PGF10, in animals receiving
sulindac, indomethacin or benoxaprofen intravenously [72].
These results are in agreement with the earlier work by
Zambraski, Chremos and Dunn showing that intravenous
sulindac (sulfide or sulfoxide) acutely reduced renal function
and prostaglandin synthesis in chronic bile duct—ligated dogs
[681. It is noteworthy that all of the aforementioned experimen-
tal studies utilized parenteral rather than oral routes of therapy.
Additional prospective clinical studies using a double—blind
crossover design in patients with significant renal insufficiency
are needed to unequivocally answer the question of renal
sparing by sulindac.
It is well established that indomethacin reduces proteinuria
and enhances the selectivity of the proteinuria in patients with
the nephrotic syndrome [96]. These effects of indomethacin
may be secondary to inhibition of renal cortical prostaglandin
synthesis, accompanied by reductions of glomerular hydro-
static pressure. De Zeeuw and coworkers have compared four
different NSAD, including sulindac, for their therapeutic effi-
cacy to decrease proteinuria in nephrotic patients [52]. Consist-
ent with a lack of prostaglandin inhibition, sulindac did not
reduce proteinuria whereas indomethacin, diclofenac and
flurbiprofen reduced proteinuria and PGE2 excretion 50 to 75%.
Reductions of proteinuria and glomerular filtration rate after
treatment with these three nonsteroidal agents correlated highly
with reduced POE2 excretion [52]. These results reinforce the
belief that sulindac has minimal capacity to inhibit renal glomer-
ular and cortical vascular eicosanoid—synthesis.
Does inhibition of renal prostaglandin synthesis blunt the
natriuretic response to furosemide?
When injected intravenously into healthy subjects, furose-
mide acutely enhances the urinary excretion of unmetabolized
prostaglandins and TXB2 [29] with no change in urinary 2,3-
dinor-6-keto-PGF1a [97], consistent with a localized intrarenal
enhancement of arachidonate availability. However, when
given orally the same drug produces a marked increase of
sodium excretion without increasing urinary prostaglandin ex-
cretion both in female volunteers and patients with essential
hypertension [98]. Reports of the effects of prostaglan-
din—synthesis inhibition on furosemide—induced natriuresis are
also conflicting, with some studies demonstrating up to 30%
blunting of the natriuretic response whereas in others there
were no significant effects [99]. As salt balance is an important
variable influencing the overall effects of cyclooxygenase inhib-
itors [100], it is not surprising to find varying results in the
literature in which salt balance has not been controlled. In dogs,
the effects of furosemide on "cortical events," that is, renal
vasodilation and renin release can be dissociated from the
natriuretic effect on the basis of a different time—course and
dose—requirement [101]. Only renal blood flow and renin secre-
tion correlate with enhanced renal PGI2 production, while the
natriuretic response has a different time course and can be
demonstrated at lower doses of the drug which do not alter
renal PG!2 synthesis [101]. Thus, furosemide—induced natriure-
sis is probably not prostaglandin—mediated, in contrast to
increases in renin release and renal blood flow. Riley et al
reached a similar conclusion by showing that, in healthy men on
a 100 mEq Na diet, the natriuretic response to intravenous
furosemide was not inhibited by either ibuprofen or sulindac,
whereas both drugs reduced the stimulation of renin release
[102]. These authors also concluded, since renin secretion was
suppressed by sulindac, that this NSAD was not "renal spar-
ing." Further animal work suggests that indomethacin reduces
the diuretic and natriuretic responses to furosemide because of
an effect on furosemide—induced renal vasodilation rather than
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an effect on tubular function or on delivery of the drug to the
ascending limb of Henle [100]. A similar conclusion has been
reached on the basis of human studies [103]. In the recent study
by Brater et al [48], however, naproxen, sulindac and ibuprofen
all significantly decreased by 14 to 34% the maximal natriuretic
response to an intravenous furosemide injection in healthy men,
despite no significant changes in urinary 6-keto-PGF1 excre-
tion and renal plasma flow. Although neither total amounts of
furosemide nor the time course of its delivery into urine were
affected by these NSAD, an alteration of early (first 10 to 15
mm) delivery of the drug to its tubular site of action could not
be excluded. In fact, only a very small change in the initial
delivery of furosemide to the ascending limb of Henle could
probably explain the observed effects on sodium excretion. The
clinical relevance of such transient acute effects of NSAD to the
maintenance of sodium excretion during chronic diuretic ther-
apy with oral furosemide has probably been overemphasized.
Does inhibition of renal prostaglandin synthesis attenuate the
antihypertensive effect of' concomitant antihypertensive
therapy?
The action of prostaglandins on blood vessels and the role of
prostaglandins in arterial hypertension have been reviewed
recently [1041. Probably renal as well as extra—renal vascular
sites of cyclooxygenase activity participate in the regulation of
blood pressure, through the release of various eicosanoids
directly acting on vascular smooth—muscle function and/or
indirectly affecting its response to vasopressor substances
[104].
No consistent effects of orally administered indomethacin on
blood pressure of healthy subjects have been described [104].
However, when given by i.v., indomethacin resulted in a
prompt increase in both systolic and diastolic blood pressure
[105], an effect possibly related to a more rapid and profound
suppression of cyclooxygenase activity and/or to its transient
nature being closely monitored. As no prostaglandin measure-
ments were reported in the vast majority of studies, the
apparent discrepancies among different investigations are diffi-
cult to reconcile. In three different studies, indomethacin was
consistently shown to enhance the pressor response to angio-
tensin II in normal man [106—108]. Most likely, the integrity of
other cardiovascular regulatory mechanisms largely accounts
for the lack of measurable changes in blood pressure associated
with prostaglandin synthesis inhibition in healthy subjects.
When administered to patients with essential hypertension
being treated with various antihypertensive agents, indometh-
acm has been shown consistently to increase both systolic and
diastolic blood pressure by 5 to 15 mm Hg [104]. The extent and
duration of such an effect varied in different investigations, and
a few studies have described an attenuation of the hypertensive
effect of indomethacin upon continued treatment [59, 109].
However, no study had assessed the long—term consequences
(>6 weeks) of such a pharmacologic interaction. Drugs whose
antihypertensive effect appeared to be attenuated by concomi-
tant administration of indomethacin include beta—adrenergic
blocking agents, thiazide diuretics, converting enzyme inhibi-
tors and various combinations of the above, thus making it
unlikely that such phenomenon reflects a specific pharmacoki-
netic interaction.
Several distinct mechanisms might account for the observed
effects of indomethacin: a) enhanced sodium retention causing
an increase of plasma volume; b) enhanced renal vascular
resistance; c) altered pressor responsiveness to angiotensin II
and/or noradrenaline; d) an inherent vasoconstrictor effect of
the drug. Although the first three mechanisms provide plausible
explanations and are compatible with reduced renal and/or
extra—renal PGI2 production, the fourth explanation should be
also considered in the light of recently—demonstrated vasocon-
strictor effects of indomethacin in the human cerebral [110] and
coronary [111] circulation, which are not shared by other
cyclooxygenase inhibitors. In comparative studies with indo-
methacin, neither aspirin (1,950 mg/day) nor naproxen (500
mg/day) significantly affected blood pressure control in treated
hypertensives [109, 112]. In contrast, piroxicam (20 mg/day)
was recently shown to blunt the antihypertensive effect of
propranolol in mild to moderate hypertensives [1131. Inasmuch
as no information on the effects of the different drugs on
prostaglandin synthesis was provided in these studies, no firm
conclusion can be reached on the involvement of renal and/or
systemic prostaglandin—synthesis inhibition in the observed
changes.
Several recent studies have demonstrated that sulindac (400
mg/day) does not attenuate the hypotensive effects of thiazides
[109, 114], beta—adrenergic blocking agents [54, 113], captopril
[601 or various combination regimens [59, 114—116]. In the study
by Puddey et al [59] and in the studies by Salvetti et al [54, 60]
indomethacin significantly reduced urinary PGE2 and/or 6-keto-
PGF1, excretion while sulindac had no effect. Wong et al
compared placebo, sulindac, naproxen and piroxicam in 20
treated hypertensive patients and found significantly higher
diastolic blood pressure and lower urine 6-keto-PGF1a after
naproxen or piroxicam therapy for four weeks, compared to
sulindac [115]. Inasmuch as sulindac does inhibit extra—renal
PGI2 production, as assessed by a dose—dependent reduction of
urinary 2,3-dinor-6-keto-PGF1a excretion during chronic dosing
[631, its lack of hypertensive effect vis-a-vis other cyclooxygen-
ase inhibitors (that is, indomethacin and piroxicam) would
argue in favor of the importance of intrarenal mechanisms a)
and b), outlined above, in mediating the hemodynamic effects of
nonselective inhibitors. This conclusion is supported by the
recent observations of Trimarco et al [117] that indomethacin as
well as ibuprofen, but not sulindac, increase blood pressure in
untreated hypertensive patients in response to a salt load. This
study suggests that renal prostaglandins participate in the renal
disposal of a chronic salt load in hypertensive patients to a
greater extent than in healthy subjects.
Clearly, further investigations are needed in order to clarify
some of the unresolved issues raised by these studies. Incor-
poration of biochemical as well as functional measurements into
future experiments and use of different cyclooxygenase inhibi-
tors should help to better define the role of renal prostaglandins
in blood pressure regulation.
Conclusions
Integrity of renal prostaglandin synthesis is necessary to
maintain renal cortical and medullary function in patients with
diverse types of disease. A comparison of the biochemical
effects of various nonsteroidal antiinflammatory drugs necessi-
tates that renal prostaglandin synthesis, as reflected by urinary
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immunoreactive prostaglandin excretion, be assessed with
proper attention to problems created by seminal fluid contam-
ination, inadequate chromatographic separation of samples,
and largely unknown cross reactivities of urinary eicosanoid
metabolites with most available antibodies. Most, but not all,
clinical studies support the observation that conventional doses
of sulindac, administered orally, do not inhibit renal prostaglan-
din synthesis or alter renal function. Caution is in order,
however, about the use of any nonsteroidal antiinflammatory
drug, including sulindac at conventional dosage, in patients
with substantial hepatic disease as the plasma levels of sulindac
sulfide are increased and prolonged compared to patients with
normal liver function. Some NSAD attenuate the efficacy of
antihypertensive therapy whereas sulindac, despite inhibition
of systemic vascular PGI2 production, does not antagonize the
antihypertensive drugs. These observations point to intrarenal,
PG-dependent mechanisms, such as NaC1 excretion, in medi-
ating the hemodynamic, that is, prohypertensive effects of
non-selective NSAD.
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